Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours

L. Santos, C. Costa, S. Pereira, Michael Koch, T. Amaro, F. Cardoso, T. Guimarães, M. J. Bento, F. Lobo, S. Pinto, C. Lopes

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: Of patients with superficial bladder cancer, a group are still at risk of disease recurrence, progression and death from their cancer after curative treatment. Angiogenesis is a crucial pathogenic mechanism for this type of urothelial cell carcinoma (UCC), and is a potential therapeutic target. However, the selection of the appropriate patients remains a dilemma. Patients and methods: Vascular endothelial growth factor (VEGF) expression and the presence of angiogenesis and occurrence of CD31, CD34, endoglin and factor VIII immunoexpression, were evaluated in 66 superficial papillary UCCs of the bladder and were correlated with classical histopathological factors and disease outcome. Results: VEGF immunoreactivity was observed in 100% of cases, and more intensely in the luminal surface. The presence of microvessel clusters independently of a fibrovascular core was observed in 22.7% of cases. Of these, the T1/G2 subgroup had an independent and significantly lower recurrence-free survival (P = 0.0002). Conclusions: These results indicate that the presence of angiogenesis in tumour urothelium is a potential prognostic factor in superficial UCC, particularly in T1/G2 tumours, and may be used to select patients for anti-angiogenic treatments.

Original languageEnglish (US)
Pages (from-to)1419-1424
Number of pages6
JournalAnnals of Oncology
Volume14
Issue number9
DOIs
StatePublished - Sep 1 2003
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Recurrence
Vascular Endothelial Growth Factor A
Carcinoma
Urothelium
Neoplasms
Factor VIII
Microvessels
Patient Selection
Disease Progression
Urinary Bladder
Therapeutics
Survival

Keywords

  • Angiogenesis
  • Bladder cancer
  • Prognosis
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. / Santos, L.; Costa, C.; Pereira, S.; Koch, Michael; Amaro, T.; Cardoso, F.; Guimarães, T.; Bento, M. J.; Lobo, F.; Pinto, S.; Lopes, C.

In: Annals of Oncology, Vol. 14, No. 9, 01.09.2003, p. 1419-1424.

Research output: Contribution to journalArticle

Santos, L, Costa, C, Pereira, S, Koch, M, Amaro, T, Cardoso, F, Guimarães, T, Bento, MJ, Lobo, F, Pinto, S & Lopes, C 2003, 'Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours', Annals of Oncology, vol. 14, no. 9, pp. 1419-1424. https://doi.org/10.1093/annonc/mdg377
Santos, L. ; Costa, C. ; Pereira, S. ; Koch, Michael ; Amaro, T. ; Cardoso, F. ; Guimarães, T. ; Bento, M. J. ; Lobo, F. ; Pinto, S. ; Lopes, C. / Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours. In: Annals of Oncology. 2003 ; Vol. 14, No. 9. pp. 1419-1424.
@article{b3efb7cdbae24f728b7ee67b6016fe6e,
title = "Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours",
abstract = "Background: Of patients with superficial bladder cancer, a group are still at risk of disease recurrence, progression and death from their cancer after curative treatment. Angiogenesis is a crucial pathogenic mechanism for this type of urothelial cell carcinoma (UCC), and is a potential therapeutic target. However, the selection of the appropriate patients remains a dilemma. Patients and methods: Vascular endothelial growth factor (VEGF) expression and the presence of angiogenesis and occurrence of CD31, CD34, endoglin and factor VIII immunoexpression, were evaluated in 66 superficial papillary UCCs of the bladder and were correlated with classical histopathological factors and disease outcome. Results: VEGF immunoreactivity was observed in 100{\%} of cases, and more intensely in the luminal surface. The presence of microvessel clusters independently of a fibrovascular core was observed in 22.7{\%} of cases. Of these, the T1/G2 subgroup had an independent and significantly lower recurrence-free survival (P = 0.0002). Conclusions: These results indicate that the presence of angiogenesis in tumour urothelium is a potential prognostic factor in superficial UCC, particularly in T1/G2 tumours, and may be used to select patients for anti-angiogenic treatments.",
keywords = "Angiogenesis, Bladder cancer, Prognosis, Vascular endothelial growth factor",
author = "L. Santos and C. Costa and S. Pereira and Michael Koch and T. Amaro and F. Cardoso and T. Guimar{\~a}es and Bento, {M. J.} and F. Lobo and S. Pinto and C. Lopes",
year = "2003",
month = "9",
day = "1",
doi = "10.1093/annonc/mdg377",
language = "English (US)",
volume = "14",
pages = "1419--1424",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours

AU - Santos, L.

AU - Costa, C.

AU - Pereira, S.

AU - Koch, Michael

AU - Amaro, T.

AU - Cardoso, F.

AU - Guimarães, T.

AU - Bento, M. J.

AU - Lobo, F.

AU - Pinto, S.

AU - Lopes, C.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Background: Of patients with superficial bladder cancer, a group are still at risk of disease recurrence, progression and death from their cancer after curative treatment. Angiogenesis is a crucial pathogenic mechanism for this type of urothelial cell carcinoma (UCC), and is a potential therapeutic target. However, the selection of the appropriate patients remains a dilemma. Patients and methods: Vascular endothelial growth factor (VEGF) expression and the presence of angiogenesis and occurrence of CD31, CD34, endoglin and factor VIII immunoexpression, were evaluated in 66 superficial papillary UCCs of the bladder and were correlated with classical histopathological factors and disease outcome. Results: VEGF immunoreactivity was observed in 100% of cases, and more intensely in the luminal surface. The presence of microvessel clusters independently of a fibrovascular core was observed in 22.7% of cases. Of these, the T1/G2 subgroup had an independent and significantly lower recurrence-free survival (P = 0.0002). Conclusions: These results indicate that the presence of angiogenesis in tumour urothelium is a potential prognostic factor in superficial UCC, particularly in T1/G2 tumours, and may be used to select patients for anti-angiogenic treatments.

AB - Background: Of patients with superficial bladder cancer, a group are still at risk of disease recurrence, progression and death from their cancer after curative treatment. Angiogenesis is a crucial pathogenic mechanism for this type of urothelial cell carcinoma (UCC), and is a potential therapeutic target. However, the selection of the appropriate patients remains a dilemma. Patients and methods: Vascular endothelial growth factor (VEGF) expression and the presence of angiogenesis and occurrence of CD31, CD34, endoglin and factor VIII immunoexpression, were evaluated in 66 superficial papillary UCCs of the bladder and were correlated with classical histopathological factors and disease outcome. Results: VEGF immunoreactivity was observed in 100% of cases, and more intensely in the luminal surface. The presence of microvessel clusters independently of a fibrovascular core was observed in 22.7% of cases. Of these, the T1/G2 subgroup had an independent and significantly lower recurrence-free survival (P = 0.0002). Conclusions: These results indicate that the presence of angiogenesis in tumour urothelium is a potential prognostic factor in superficial UCC, particularly in T1/G2 tumours, and may be used to select patients for anti-angiogenic treatments.

KW - Angiogenesis

KW - Bladder cancer

KW - Prognosis

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0141613774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141613774&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdg377

DO - 10.1093/annonc/mdg377

M3 - Article

C2 - 12954582

AN - SCOPUS:0141613774

VL - 14

SP - 1419

EP - 1424

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 9

ER -